Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3E10-D31N
- Development stage
- Preclinical
- Lead developer
- Gennao Bio
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
3E10-D31N (also known as GMABD31N) is a preclinical cell-penetrating monoclonal antibody fragment (scFv) developed by Gennao Bio using its proprietary GMAB technology platform. It is an engineered version of the 3E10 anti-DNA autoantibody, featuring a D31N mutation in the CDR1 region that enhances its nuclear penetration and DNA-binding affinity. The antibody utilizes the equilibrative nucleoside transporter 2 (ENT2) to gain entry into cells and localize to the nucleus. 3E10-D31N acts as a non-viral delivery vehicle by forming non-covalent complexes with various nucleic acid therapeutics, including mRNA, siRNA, DNA, and antisense oligonucleotides, facilitating their intracellular delivery. It is currently being investigated for applications in oncology and the treatment of rare monogenic skeletal muscle diseases.
- Other names
- 3E10 D31NGMAB
02
Targets
RAD51 (RAD51 Recombinase)ENT2 (Equilibrative nucleoside transporter 2)
Beyond the preview
Go deeper on 3E10-D31N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3E10-D31N.